[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366586-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366586-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-critical-review-on-bh3-mimetic-drugs-and-the-treatment-of-cancer-associated-thrombosis-cat-a-proposed-design-for-a-drug-delivery-system-capable-of-simultaneously-targeting-tumor-cells-and-activated-platelets","A Critical Review on BH3 Mimetic Drugs and the Treatment of Cancer-Associated Thrombosis (CAT) - A Proposed Design for a Drug Delivery System Capable of Simultaneously Targeting Tumor Cells and Activated Platelets","","The review examines BH3-mimetic drugs as programmed cell-death inducers designed to selectively target cancerous states while limiting effects on healthy tissues. It highlights a key therapeutic challenge: platelet damage, particularly thrombocytopenia, may occur because platelets—being anucleated—are highly susceptible to apoptosis, especially with earlier BH3-mimetic versions. Cancer conditions simultaneously elevate thrombosis and thromboembolism risk, creating a rationale to consider certain BH3 mimetics for cancer-associated thrombosis (CAT) therapy. The article proposes a drug-carrier platform enabling conserved co-delivery to cotarget tumor cells and activated platelets at CAT sites, aiming for improved safety and efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-critical-review-on-bh3-mimetic-drugs-and-the-treatment-of-cancer-associated-thrombosis-cat-a-proposed-design-for-a-drug-delivery-system-capable-of-simultaneously-targeting-tumor-cells-and-activated-platelets/366586/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-critical-review-on-bh3-mimetic-drugs-and-the-treatment-of-cancer-associated-thrombosis-cat-a-proposed-design-for-a-drug-delivery-system-capable-of-simultaneously-targeting-tumor-cells-and-activated-platelets/366586.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic goal does the review focus on when discussing BH3-mimetic drugs?","Question",{"text":63,"@type":64},"It focuses on inducing programmed cell demise against tumors with selective targeting of the cancerous state while minimizing side effects on healthy tissues and cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why can BH3-mimetic drugs lead to platelet-related complications in cancer patients?",{"text":68,"@type":64},"The review explains that platelets are vulnerable to apoptosis, and some BH3-mimetic versions can simultaneously damage platelets and cancer cells, manifesting mainly as thrombocytopenia.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the proposed approach address cancer-associated thrombosis (CAT)?",{"text":72,"@type":64},"It proposes a specific drug-carrier platform for direct and conserved co-delivery of BH3-mimetics to effectively cotarget cancer cells and activated platelets at the site of CAT.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366586,1790612717,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Medicine  \n|  REVIEW  OPEN ACCESS \u003Cbr>A Critical Review on BH3 Mimetic Drugs and the Treatment of Cancer-Associated Thrombosis (CAT):\u003Cbr>A Proposed Design for a Drug Delivery System Capable of Simultaneously Targeting Tumor Cells and Activated Platelets\u003Cbr>Mehran Ghasemzadeh1  | Nazanin Heidari1 | Jalal Naghinezhad1 | Alireza Ghasemzadeh2 | Ehteramolsadat Hosseini1\u003Cbr>1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran | 2School of Medicine, Iran University of Medical Sciences, Tehran, Iran\u003Cbr>Correspondence: Mehran Ghasemzadeh ([mehran1476@yahoo.com](mehran1476@yahoo.com)) | Ehteramolsadat Hosseini ([e.hosseini10@yahoo.com.au](e.hosseini10@yahoo.com.au))\u003Cbr>Received: 14 November 2024 | Revised: 12 August 2025 | Accepted: 12 September 2025\u003Cbr>Funding: The authors received no specific funding for this work.\u003Cbr>Keywords: apoptosis | BH3 mimetic | cancer | drug delivery system | nanoparticle | necrosis platelet | RGD | thrombocytopenia | thrombosis |\n| --- |\n| ABSTRACT\u003Cbr>Background: Induction of programmed cell demise against tumors that achieves selective targeting of the cancerous state without side effects on healthy tissues and cells is the most challenging therapeutic goal to eradicate cancer progression. In this regard, several BH3-mimetic drugs have been designed to induce apoptosis in cancer cells with acceptable specificity and fewer adverse events.\u003Cbr>Implications: Taking all considerations into account, even the latest versions of-BH3 mimetics or some other systemic anticancer drugs may affect platelets, mainly manifested by thrombocytopenia in cancer patients who are per se at major risk of hemostatic complications. This is mainly due to the fact that platelets, as anucleated cells, are more vulnerable to apoptosis, especially induced by earlier versions of BH3-mimetics. On the other hand, the cancerous state, particularly in its aggressive conditions, is usually associated with the risk of thrombosis and thromboembolism. Therefore, given that some earlier versions of BH3-mimetics have the potential to simultaneously damage platelets and cancer cells, they may be considered as a therapeutic choice for the treatment of cancer-associated thrombosis (CAT) . However, this is subject to the design of a specific platform of drug carriers that supports cancer targeting without interfering with other tissues and cells. The critical review presented here first provides an overview of the various BH3-mimetic drugs available, highlighting ongoing development to enhance their safety and efficacy. Then, by introducing studies on the direct delivery of BH3-mimetics, this review finally proposes an innovative approach for the “conserved conveyance” of drugs to effectively cotarget cancer cells and activated platelets at the site of CAT. |\n|  |\n| Abbreviations: ADAMs, A disintegrin and metalloproteinase; ANT, adenine nucleotide translocator; ATP, adenosine triphosphate; BAD, BCL2 associated agonist of cell death; BAK, Bcl-2 antagonist/killer; BAX, BCL2 Associated X; BCL-2, B cell lymphoma-2; BCL-xL, B-cell lymphoma-extra large; CAF, cancer-associated fibroblasts; CAT, cancer-associated thrombosis; CLEC-2, C-type lectin receptor 2; CypD, cyclophilin D; DAMPs, damage-associated molecular patterns; DDS, drug delivery system; DIC, disseminated intravascular coagulation; DTS, dense tubular system; DVT, deep vein thrombosis; FAP, fibroblast activating protein; FDA, Food and Drug Administration; G-CSF, granulocyte colony stimulating factor; Mcl-1, myeloid cell leukemia 1; MOMP, mitochondrial outer membrane permeabilization; MPTP, mitochondrial permeability transition pore; NET, neutrophil extracellular traps; PAI-1, plasminogen activator inhibitor-1; PE, pulmonary embolism; PS, phosphatidylserine; Q-VD-OPh, Quinoline-Val-Asp-Difluorophenoxymethylketone; RGD, Arg-Asp-Gly; ROS, reactive oxygen species; TF, tissue factor; TfR1, transferrin receptor 1; TLRs, toll-like recep","cbCaivBIc9NzEuII","https://ap.wps.com/l/cbCaivBIc9NzEuII","pdf",2328355,"English","# Abstract\n# Abbreviations\n# Conclusion\n# Introduction","[{\"question\":\"What therapeutic goal does the review focus on when discussing BH3-mimetic drugs?\",\"answer\":\"It focuses on inducing programmed cell demise against tumors with selective targeting of the cancerous state while minimizing side effects on healthy tissues and cells.\"},{\"question\":\"Why can BH3-mimetic drugs lead to platelet-related complications in cancer patients?\",\"answer\":\"The review explains that platelets are vulnerable to apoptosis, and some BH3-mimetic versions can simultaneously damage platelets and cancer cells, manifesting mainly as thrombocytopenia.\"},{\"question\":\"How does the proposed approach address cancer-associated thrombosis (CAT)?\",\"answer\":\"It proposes a specific drug-carrier platform for direct and conserved co-delivery of BH3-mimetics to effectively cotarget cancer cells and activated platelets at the site of CAT.\"}]","A Critical Review on BH3 Mimetic Drugs and the Treatment of Cancer-Associated Thrombosis (CAT) - A Proposed Design for a Drug Delivery System Capable of Simultaneously Targeting Tumor Cells and Activated Platelets | PDF",1790166266,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dcb35722b84fc20e92cced625bf9b40.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/297ffc608b98f235aa0bbd4ae3b07053.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9369402acd006f1e56c037401727e249.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3394211bca4c20097e8f1c979c8b375.webp",980,1287]